What is Oaktree Specialty's gross profit margin?

What is the revenue and EPS growth rate for Oaktree Specialty year over year?

What is the market's earnings forecast for Oaktree Specialty next quarter?

What were the key takeaways from Oaktree Specialty's earnings call?

What does Oaktree Specialty do and what are its main business segments?

What factors drove the changes in Oaktree Specialty's revenue and profit?

Did Oaktree Specialty beat or miss consensus estimates last quarter?

What guidance did Oaktree Specialty's management provide for the next earnings period?

- **Stable Earnings Despite Rate Cuts**: Q1 NII of $36.1 million fully covered dividend, despite lower base rates.
- **Active Deployment**: $314 million new investments at 525 bps spreads, 9% yields, and 92% first lien senior secured debt.
- **Software Portfolio Resilience**: 23% of assets with 18% repayments over 12 months, 92% first lien coverage.
- **AI Cautious Optimism**: Selective investments in software with control points, while monitoring 2 ARR-based loans.
- **Liquidity Strength**: $576 million available, supporting continued capital deployment.

**【Management Opening Remarks】**
- Adjusted net investment income (NII) for Q1 2026 was $36.1 million ($0.41 per share), up modestly from $35.4 million ($0.40 per share) in Q4 2025.
- Fully covered quarterly dividend of $0.40 per share, reflecting stable earnings despite lower base rates.
- New fund investments totaled $314 million (up 42% QoQ), with all-in spreads of 525 bps and yields of 9%.
- Nonaccruals stable at 3.1% of debt portfolio (fair value), with restructuring of Avery loan improving recovery prospects.

**【CEO Commentary】**
- Private credit market bifurcated: disciplined sponsors access capital, while weaker firms struggle.
- Direct lending spreads bottomed at SOFR +450-475 bps; 150 bps premium vs. broadly syndicated loans.
- Software portfolio (23% of investments) prioritizes control points, data gravity, and AI roadmaps.
- 18% of software positions repaid over 12 months, with 92% as first lien term loans.
- Cautious optimism on AI: winners will have execution speed, while losers face dispersion.

**【CFO Financial Commentary】**
- Adjusted NII of $36.1 million, up 2% QoQ, driven by lower Part I incentive fees.
- NAV per share $16.30 (down 2% QoQ) due to Pluralsight markdown; total investment income $74.5 million (down 3% QoQ).
- Net leverage 1.07x (up from 0.97x), with $576 million liquidity ($81M cash, $495M undrawn credit).
- JVs generated 12% ROE, with $511 million in broadly syndicated loans.

**【Q&A Highlights】**
- **Underperforming Assets**: 11 nonaccruals (3.1% of portfolio), mostly public tech loans with small CLO selling.
- **AI Risks**: Focus on ARR-based loans (2% of fair value) with strong sponsor support.
- **Software Trends**: 20% EBITDA growth, 18% repayments, and 47% LTV at underwrite.
- **LTV Thresholds**: 60%+ LTV may trigger refinancing challenges, with 2 ARR loans nearing covenant conversion.

Oaktree Specialty Lending Corporation (OCSL) Q1 2026 Earnings Call Transcript

- **NII growth and dividend stability**: Q4 NII of $0.40 per share (up 8.1% QoQ) supports $0.40 dividend, with plans to offset lower rates through leverage and nonaccrual resolution.
- **Portfolio diversification and yield**: 88% of new investments in first lien loans, 40% of portfolio companies marked up 70 bps, and 83% of debt investments in first lien senior secured debt.
- **Market dynamics**: Spreads stabilized at SOFR + 450, with disciplined PIK usage (6.4% of income) and selective deal flow.
- **Leverage and liquidity**: 0.97x leverage ratio (target 0.9x-1.25x), $695 million liquidity to support deployment.

**【CEO Summary Section】**
- Adjusted net investment income (NII) for Q4 2025 was $0.40 per share, up from $0.37 in Q3, driven by normalized prepayment fees, higher dividend income, and lower interest expense.
- Nonaccruals decreased to 2.8% of the portfolio (fair value basis) at year-end, down 20 basis points from Q3 and 100 basis points year-over-year.
- Board approved a $0.40 per share dividend, consistent with Q4 earnings, with plans to offset lower base rates through increased leverage, JV optimization, and nonaccrual resolution.

**【Market Environment Commentary】**
- Private credit deal flow showed modest improvement, with mixed quality and increased dual-track financings in the broadly syndicated market.
- Spreads stabilized at SOFR + 450 post-Fed rate cut, with cautious optimism on price discipline.
- PIK usage remained disciplined at 6.4% of total investment income, focused on high ROE projects.

**【Portfolio & Investment Activity】**
- New funded commitments reached $220 million (QoQ +54%), with a 88% allocation to first lien loans.
- Notable investment: $2.5 billion FILO for Walgreens Boots Alliance at SOFR + 700 with 2.5% OID, reflecting complex deal execution capabilities.
- Portfolio yield on debt investments was 9.8%, with 83% in first lien senior secured debt.
- Over 40% of portfolio companies saw markups of ~70 basis points, driven by improving fundamentals.

**【Financial Results】**
- Q4 NII was $35.4 million ($0.40 per share), up from $32.5 million ($0.37 per share) in Q3, supported by higher prepayment fees and lower borrowing costs.
- Weighted average cost of borrowings decreased to 6.5%, with leverage ratio at 0.97x (target range 0.9x-1.25x).
- Liquidity of $695 million (including $80 million cash and $615 million undrawn credit facility) supports capital deployment.

**【Q&A Highlights】**
- Q4 2025 investment activity expected to remain steady, with no outsized repayments anticipated.
- Spread tightening in Q4 driven by market competition, with selective deployment strategy.
- Nonaccruals in healthcare/pharma sectors reflect long-standing operational workouts, with no near-term resolution.
- Walgreens deal's high spread (SOFR + 700) unlikely to repeat in Q4, but pipeline includes potential complex deals.


Oaktree Specialty Lending Corporation (OCSL) Q4 2025 Earnings Call Transcript

- **NAV and Dividend Stability**: NAV up slightly, $0.40 dividend approved amid 0.93x leverage and $730M liquidity.
- **Market Resilience**: Middle-market spreads at SOFR +425-475bp, with asset-backed and European opportunities.
- **Portfolio Strength**: Nonaccruals down to 9% (from 10%), $25.7M Mosaic recovery, and first lien deals at 9.1% yield.
- **Financial Discipline**: 6.6% WAC, $3.9M one-time costs, and JV ROE of 10.5%.
- **Growth Catalysts**: $730M dry powder, pipeline diversification, and rating agency support for leverage expansion.

**【President's Overview】**
- NAV increased slightly, with adjusted NII of $0.37 per share, down due to refinancing costs and lower nonrecurring income.
- Dividend of $0.40 per share approved, supported by balance sheet strength (leverage at 0.93x, lowest in 3 years) and $730M liquidity.
- Refinancing reduced interest expense: amended credit facility lowered rate to SOFR +1.75-1.875%, replacing higher-cost ABL.

**【CEO Market Commentary】**
- M&A activity muted; lending focused on refinancing, with CLO issuance pulling deals into broadly syndicated market.
- Private credit spreads tightened but remain attractive vs. liquid credit. Middle-market spreads at SOFR +425-475bp, core/middle at +25-50bp higher.
- Opportunities in asset-backed, life sciences, Europe, and Asia. Credit quality stable, with risks tied to company-specific issues.

**【Co-CIO Portfolio Update】**
- New investments: Draken Intl (SONIA +550bp, $31.9M) and Lyons Magnus (SONIA +450bp, $12.7M), both first lien.
- Nonaccruals improved: -1% as share of fair value (10% → 9%), with Mosaic recovery ($25.7M) and Telestream exit.
- Pipeline remains robust, with focus on mature, cash-generative businesses and diversified industry exposure.

**【CFO Financial Results】**
- Q3 NII: $32.5M ($0.37), down 16% vs. prior quarter due to $3.9M one-time financing costs and lower nonrecurring income.
- Interest expense: 6.6% WAC, down from 6.7%. Leverage at 0.93x, near low end of 0.9-1.25x target.
- JV performance: $442M in broadly syndicated loans, 10.5% ROE, 1.3x leverage.

**【Q&A Highlights】**
- Spread achievement: mid-500s via lower spreads, life sciences, European deals, and refinancing premium.
- Leverage strategy: target midpoint (1.075x), with plans to deploy $730M liquidity and reduce nonaccruals.
- Dividend confidence: Board approval reflects normalized earnings, with visibility into repayments and asset redeployment.
- Asset-backed focus: equipment receivables, telecom/fiber optics, avoiding consumer unsecured debt.

Oaktree Specialty Lending Corporation (OCSL) Q3 2025 Earnings Call Transcript

- **Challenges Persist**: Q2 NII down 15% to $0.45/share due to non-accruals and rate cuts, despite $100M+ repayments.
- **Portfolio Restructuring**: 4.6% of portfolio on non-accrual, with 50%+ recoveries in Mosaic and Avery sales.
- **Market Caution**: Tariffs and high rates slow M&A, but Oaktree remains active in >$150M EBITDA direct lending.
- **JV Outperformance**: 10.6% ROE vs. 10.2% Q1, potential to expand if credit spreads widen.
- **Leverage Optimization**: Net leverage at 0.93x (low end of target range), $1.1B dry powder for selective deployment.

**【Matt Pendo: Performance Overview】**
- Adjusted NII: $39M ($0.45/share) vs. $45M ($0.54/share) Q1, driven by non-accruals and lower reference rates.
- NAV: $16.75/share (-5.1% QoQ) due to $13M write-downs on 4.6% of portfolio on non-accrual.
- Dividend: Base $0.40 + supplemental $0.02 (total $0.42), aligned with new policy.
- Capital Structure: Refinanced $200M 2025 bonds into 2030 notes, reducing interest rate by 25-125bps.

**【Armen Panossian: Portfolio & Market Update】**
- **New Non-Accruals**: 
  - Mosaic (76% markdown post-50% repayment)
  - SiO2 (69% markdown despite new contracts)
  - Dialyze (76% markdown, <1% of portfolio)
- **Investment Activity**: 
  - $407M deployed in 32 deals (84% senior secured)
  - Notable loans: Vantive ($61M) & Barracuda ($15.5M)
- **Market Trends**: 
  - Tariffs slowing M&A and capital deployment
  - Larger, diversified borrowers preferred (median EBITDA $158M)
  - Liquid credit exits slowed to $279M Q2 vs. $512M Q1

**【Chris McKown: Financial Details】**
- **Income Statement**: 
  - NII: $38.7M (-15% QoQ) due to lower interest income
  - Total investment income: $124.3M (-8% QoQ)
  - Interest expense: $34.4M (-10% QoQ) from rate cuts
- **Balance Sheet**: 
  - Net leverage: 0.93x (low end of 0.9-1.25x target)
  - Liquidity: $1.1B (cash $98M + undrawn credit $1B)
  - JV performance: 10.6% ROE vs. 10.2% Q1

**【Q&A Highlights】**
- **Market Strategy**: 
  - Focused on >$150M EBITDA borrowers with tariff resilience
  - JV leverage may increase if public credit volatility persists
- **NII Run Rate**: 
  - Current $0.45/share is stable, but deployment pace uncertain
  - JV returns could expand to 11-12% if spreads widen
- **Tariff Impact**: 
  - 2025Q2 too early to assess, but 2025H2 earnings at risk
  - Proactively selling tariff-exposed liquid credits

Oaktree Specialty Lending Corporation (OCSL) Q2 2025 Earnings Call Transcript

- **Strategic Reinvestment**: Oaktree's $100M equity purchase at 10% premium signals confidence, adding $200M+ deployment capacity. 
- **Fee Structure Reset**: Permanent total return hurdle caps fees, aligning incentives with long-term performance. 
- **Stable Dividend Policy**: $0.40 base + 50% excess allocation to supplements provides stability amid market cycles. 
- **Portfolio Resilience**: 82% first lien, 5.4x median leverage, 2.1x interest coverage highlight credit quality. 
- **2025 Growth Catalysts**: $2T+ PE dry powder, declining rates, and regulatory tailwinds set up for active deal flow.

**【Strategic Actions Overview】**
- Oaktree purchased $100 million of OCSL common stock at a 10% premium to market price, increasing NAV by 7%. 
- Introduced a total return hurdle for Part 1 incentive fees with a 12-quarter lookback period by FY2027. 
- Waived $6.2 million in Q1 Part 1 fees under new structure. 
- Implemented base + supplemental dividend policy: $0.40 base + $0.07 supplemental Q1 2025, with ~50% of excess NII allocated to supplements.

**【Portfolio Performance】**
- $2.8B portfolio at 10.7% weighted average yield, 82% in first lien. 
- 3.9% of portfolio on nonaccrual (Dominion Diagnostics, Dialyze), with $62M in restructured assets. 
- 50%+ of portfolio companies have >$100M EBITDA, 2.1x interest coverage.

**【Market Outlook】**
- 2025 expected to be active with $2T+ PE dry powder, improving deal flow. 
- First lien lending at 9-10% yields seen as attractive vs. junior risk. 
- Fed rate cuts may ease borrowing costs but rates unlikely to return to pre-2022 lows.

**【Financial Results】**
- Adjusted NII: $45M ($0.54/share) vs. $45.2M ($0.55) prior quarter. 
- NAV: $17.63 vs. $18.09 prior quarter. 
- Net leverage: 1.03x (down from 1.07x). 
- Liquidity: $1.1B (including $100M new equity).

OCSL

OCSL fundamentals

Earnings Call

You can ask Aime